Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation

The recruitment status of this study is unknown because the information has not been verified recently.

Verified June 2008 by University of California, Los Angeles.
Recruitment status was Recruiting

Sponsor:

Collaborator:

Genzyme

Information provided by:

University of California, Los Angeles

ClinicalTrials.gov Identifier:

NCT00592306

First received: December 28, 2007

Last updated: June 4, 2008

Last verified: June 2008

History of Changes

Purpose

The purpose of this study is to take a population of lung transplant recipients who meet UCLA criteria for induction chemotherapy with thymoglobulin and prospectively study weather giving the first dose intraoperatively versus postoperatively makes a difference with how patients do during and after lung transplantation. In addition, these cohorts will be compared to patients who do not qualify for thymoglobulin and receive either an alternative agent or no agent. The primary endpoint is primary graft dysfunction. We will also evaluate several other early and late end points such as ventilator days, ICU/hospital days, acute/chronic rejection, infection, CT chest abnormalities, and survival.

We will also collect donor lung tissue and lavage fluid for measurement of various proteins and receptor expression at two time points: (1) prior to implementation and dosing of induction chemotherapy and (2) after transplantation (following a course of induction chemotherapy). This will allow us to possibly make a connection between the profiles of the various proteins and receptors and the clinical outcomes, depending on weather the patient has received induction chemotherapy, starting intraoperatively or postoperatively.

Condition	Intervention	Phase
Lung Transplant	Drug: rabbit antithymocyte globulin + placebo Drug: placebo + rabbit antithymocyte globulin	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Prevention
Official Title:	A Prospective Single Center Randomized Trial of Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation.

Resource links provided by NLM:

MedlinePlus related topics: Lung Transplantation

Drug Information available for: Antilymphocyte Serum

U.S. FDA Resources

Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:

Primary Graft Dysfunction [ Time Frame: paO2/FiO2 ratio at post transplant, 24 hr, and 48 hr time points ] [ Designated as safety issue: No ]

Estimated Enrollment:	120
Study Start Date:	January 2006
Estimated Study Completion Date:	September 2009
Estimated Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: I We plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)	Drug: rabbit antithymocyte globulin + placebo All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered. Each arm will also receive a single placebo dose. Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses. Other Name: thymoglobulin
Experimental: II We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)	Drug: placebo + rabbit antithymocyte globulin All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered. Each arm will also receive a single placebo dose. Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin.

Arms

Assigned Interventions

Active Comparator: I

We plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)

Drug: rabbit antithymocyte globulin + placebo

All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.

Each arm will also receive a single placebo dose.

Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses.

Other Name: thymoglobulin

Experimental: II

We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)

Drug: placebo + rabbit antithymocyte globulin

All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.

Each arm will also receive a single placebo dose.

Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

On a voluntary basis, all patients eligible for bilateral lung transplantation between the ages of 18-65 years (inclusive)

Exclusion Criteria:

Have any known allergy to horse or rabbit antithymocyte polyclonal agents
Have a preoperative platelet count less then 100,000/mm3
Are recipients of multiple organ transplants (either simultaneous or sequential)
Are recipients of a single lung transplantation
Have a contraindication to rabbit antithymocyte globulin based on judgement of the investigators (i.e. bleeding diathesis or overwhelming risk of intense immunosuppression) including the following patients: greater than 65 years of age, prior diagnosis of malignancy (with the exception skin malignancies), underlying suppurative lung disease (i.e. bronchiectasis, cystic fibrosis, etc.).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00592306

Contacts

Contact: Rajan Saggar, M.D.	310-825-5635	rsaggar@mednet.ucla.edu
Contact: Michaela Dyke	310-825-5635	mdyke@mednet.ucla.edu

Locations

United States, California
Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA	Recruiting
Los Angeles, California, United States, 90095-1690
Contact: Rajan Saggar, M.D. 310-825-5635 rsaggar@mednet.ucla.edu
Contact: Michaela Dyke 310-825-5635 mdyke@mednet.ucla.edu
Principal Investigator: Rajan Saggar, M.D.
Sub-Investigator: David J Ross, M.D.
Sub-Investigator: John Belperio, M.D.
Sub-Investigator: Joseph P Lynch, III, M.D.
Sub-Investigator: Abbas Ardehali, M.D.
Sub-Investigator: Bernard Kubak, MD
Sub-Investigator: Rajeev Saggar, MD
Sub-Investigator: Sam Weigt, MD
Sub-Investigator: Aric Gregson, MD

Sponsors and Collaborators

University of California, Los Angeles

Genzyme

Investigators

Principal Investigator:

Rajan Saggar, MD

Department of Pulmonology and Critical Care at David Geffen School of Medicine at UCLA

More Information

No publications provided

Responsible Party:	Rajan Saggar, David Geffen School of Medicine, UCLA
ClinicalTrials.gov Identifier:	NCT00592306 History of Changes
Other Study ID Numbers:	ATG in Lung Transplantation
Study First Received:	December 28, 2007
Last Updated:	June 4, 2008
Health Authority:	United States: Food and Drug Administration

Keywords provided by University of California, Los Angeles:

ATG
rabbit thymoglobulin
reperfusion lung injury
primary graft dysfunction
lung transplantation

Additional relevant MeSH terms:

Antilymphocyte Serum
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013

To Top